Farris F F, King F G, Dedrick R L, Litterst C L
J Pharmacokinet Biopharm. 1985 Feb;13(1):13-39. doi: 10.1007/BF01073654.
A physiological model has been developed to describe the disposition of cis-dichlorodiammine-platinum(II) (DDP) following i.v. dosing in the female rat bearing the Walker 256 carcinoma. The model simulates concentrations of DDP and its mobile and fixed metabolites in plasma, liver, gut, skin, muscle, tumor, carcass, and kidney, and DDP and mobile metabolite excretion following a 4 mg/kg dose. In the kinetic model, DDP binds irreversibly to low MW nucleophiles and macromolecules (largely proteins) within the plasma and tissue compartments to form mobile and fixed metabolites, respectively. Reaction rates for the formation of each metabolite are tissue/organ specific. The rate constant for the biotransformation of DDP to fixed metabolite in plasma (k2P = 0.0082 min-1) was determined from in vitro incubation studies. This rate was used as the basis for estimating the biotransformation rate constants for DDP to fixed and mobile metabolites in other compartments. Both DDP and mobile metabolite are assumed to follow flow-limited transport, to freely traverse compartmental barriers, and to partition equally in all compartments. Both are excreted in the urine, the major route of Pt elimination. Urinary excretion is modeled as a linear process involving filtration only; an assumption based on a calculated renal clearance of 1.1 ml/min, a value very similar to the estimated GFR. Biliary excretion is a minor route of mobile metabolite elimination and is modeled as a linear process occurring in the liver. Four hours after dosing, approximately 60% of the administered Pt remains in the tissues and plasma. Of this, over 75% of the plasma Pt and 90% of the metal ion in every other compartment is fixed (protein bound). Fixed Pt can be eliminated from a compartment only after its biotransformation to mobile metabolite. In most compartments this rate of elimination corresponds closely to the average rate of protein turnover in that compartment.
已建立一种生理学模型,用于描述顺二氯二氨铂(II)(DDP)在患有Walker 256癌的雌性大鼠静脉注射给药后的处置情况。该模型模拟了4mg/kg剂量给药后,DDP及其可移动和固定代谢产物在血浆、肝脏、肠道、皮肤、肌肉、肿瘤、 carcass和肾脏中的浓度,以及DDP和可移动代谢产物的排泄情况。在动力学模型中,DDP分别与血浆和组织隔室内的低分子量亲核试剂和大分子(主要是蛋白质)不可逆结合,形成可移动和固定代谢产物。每种代谢产物形成的反应速率具有组织/器官特异性。通过体外孵育研究确定了血浆中DDP向固定代谢产物生物转化的速率常数(k2P = 0.0082 min-1)。该速率用作估计DDP在其他隔室中向固定和可移动代谢产物生物转化速率常数的基础。假定DDP和可移动代谢产物均遵循流量限制运输,可自由穿过隔室屏障,并在所有隔室中均匀分配。两者均通过尿液排泄,这是铂消除的主要途径。尿液排泄被模拟为仅涉及过滤的线性过程;该假设基于计算得出的肾清除率为1.1 ml/min,该值与估计的肾小球滤过率非常相似。胆汁排泄是可移动代谢产物消除的次要途径,被模拟为在肝脏中发生的线性过程。给药后4小时,约60%的给药铂保留在组织和血浆中。其中,超过75%的血浆铂和其他每个隔室中90%的金属离子是固定的(与蛋白质结合)。固定铂只有在生物转化为可移动代谢产物后才能从隔室中消除。在大多数隔室中,这种消除速率与该隔室中蛋白质周转的平均速率密切对应。